

KRAS mutation in advanced lung cancer: Response to Apatinib and clinical outcomes

Yang Yuan¹ and Ma Qianli²

¹Kunming Medical University, China

²Yunnan Cancer Hospital, China



Abstract

Lung cancer is a malignant respiratory tumor with rapid development and poor prognosis. VATS(video-assisted thoracic surgery) is the main treatment for early lung cancer, but the majority of patients are diagnosed at stage IIIB or IV. Platinum-based chemotherapy regimen is currently considered key components of first-line chemotherapy for advanced lung cancer; however, there are no standard treatment plans for lung cancer with KRAS mutation. Apatinib has been successfully applied as third-line treatment for advanced gastric cancer and has shown high efficacy in the treatment of various cancer. Herein we report a case of advanced lung cancer harboring KRAS mutation in which apatinib was administered and a partial response was achieved after four months of treatment. To date, a 10 months of progression-free survival have been achieved. Adverse reactions can be controlled and the patient's quality of life has improved. Apatinib provides a new option for clinicians to treat patients with advanced KRAS-mutation lung cancer.

2. A cecropin-like antimicrobial peptide with anti-inflammatory activity from the black fly salivary glands; *Parasites & Vectors*/Volume 8/Issue1
3. Inhibition of Rac1 Activity in the Hippocampus Impairs the Forgetting of Contextual Fear Memory; *Molecular Neurobiology*/Volume 53/Issue2
4. The Bidirectional Effects of Hypothyroidism and Hyperthyroidism on Anxiety- and Depression-Like Behaviors in Rats; *Hormones and Behavior*/ Volume 69
5. Fluoxetine treatment reverses the intergenerational impact of maternal separation on fear and anxiety behaviors; *Neuropharmacology*/Volume92

[19th Annual Congress on Pharmaceutics & Drug Delivery Systems](#) June 18-19, 2020 Webinar

Abstract Citation:

Yang Yuan, KRAS mutation in advanced lung cancer: Response to apatinib and clinical outcomes, *Euro Pharmaceutics 2020, 19th Annual Congress on Pharmaceutics & Drug Delivery Systems* June 18-19, 2020 Webinar.

(<https://pharmaceutics.annualcongress.com/abstract/2020/kras-mutation-in-advanced-lung-cancer-response-to-apatinib-and-clinical-outcomes>)



Biography:

Yang Yuan has completed his master at the age of 27 years from Kunming Medical University. He is currently engaged in basic and clinical research of lung cancer. He has published more than 10 papers in journals around the world and has been serving as an oncology member of CSCO.

Speaker Publications:

1. Caregiving burden and gain among adult-child caregivers caring for parents with dementia in China: the partial mediating role of reciprocal filial piety; *International Psychogeriatrics*/Volume1/Issue 11